Amiodarone in ventricular arrhythmias: still a valuable resource?
| Autor: | Pasquale Vergara, Daniele Zacchetti, Paolo Della Bella, Alberto Margonato, Giovanni Landoni, Lorenzo Malatino, Gabriele De Blasi, Francesco Melillo, Paolo Ossola, Luca Baldetti, Lorenzo Cianfanelli, Antonio Frontera, Luigia Brugliera, Giulio Falasconi, Simone Gulletta, Giuseppe D’Angelo, Luigi Pannone |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Left
heart failure Arrhythmias Cardiac Stroke Volume General Medicine Arrhythmias Sudden Ventricular Function Left Defibrillators Implantable Death Death Sudden Cardiac RC666-701 catheter ablation cardiovascular system Humans Ventricular Function Diseases of the circulatory (Cardiovascular) system ventricular tachycardia Implantable pharmacology Cardiology and Cardiovascular Medicine Anti-Arrhythmia Agents Cardiac amiodarone Defibrillators |
| Zdroj: | Reviews in Cardiovascular Medicine, Vol 22, Iss 4, Pp 1383-1392 (2021) |
| ISSN: | 2153-8174 |
| DOI: | 10.31083/j.rcm2204143 |
| Popis: | Ventricular arrhythmias still represent an important cause of morbidity and mortality, especially in patients with heart failure and reduced left ventricular ejection fraction. Amiodarone is a Class III Vaughan-Williams anti-arrhythmic drug widely used in ventricular arrhythmias for its efficacy and low pro-arrhythmogenic effect. On the other hand, a significant limitation in its use is represented by toxicity. In this review, the pharmacology of the drug is discussed to provide the mechanistic basis for its clinical use. Moreover, all the latest evidence on its role in different clinical settings is provided, including the prevention of sudden cardiac death, implanted cardioverter defibrillators, ischemic and non-ischemic cardiomyopathies. A special focus is placed on everyday clinical practice learning points, such as dosage, indications, and contraindications from the latest guidelines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|